ebselen has been researched along with Subarachnoid Hemorrhage in 4 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action, on the outcome of subarachnoid hemorrhage was evaluated in a multicenter placebo-controlled double-blind clinical trial." | 9.08 | Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. ( Abe, H; Asano, T; Ishibashi, S; Kikuchi, H; Ohta, T; Saito, I; Sano, K; Takakura, K; Yoshimoto, T, 1998) |
| "We investigated the effect of ebselen relative to nimodipine in an animal model of subarachnoid hemorrhage." | 7.76 | Effects of ebselen versus nimodipine on cerebral vasospasm subsequent to experimental subarachnoid hemorrhage in rats. ( Acikgoz, B; Acikgoz, S; Ankarali, H; Bahadir, B; Bektas, S; Gul, S; Hanci, V; Kalayci, M; Ugurbas, E, 2010) |
| " The monkeys were randomly divided into three groups according to Ebselen dosage: 1) no dosage or non-treated group; 2) high-dose Ebselen group; and 3) low-dose Ebselen group." | 5.31 | Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates. ( Handa, Y; Kaneko, M; Kobayashi, H; Kubota, T; Takeuchi, H; Tsuchida, A, 2000) |
| "The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action, on the outcome of subarachnoid hemorrhage was evaluated in a multicenter placebo-controlled double-blind clinical trial." | 5.08 | Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. ( Abe, H; Asano, T; Ishibashi, S; Kikuchi, H; Ohta, T; Saito, I; Sano, K; Takakura, K; Yoshimoto, T, 1998) |
| "We investigated the effect of ebselen relative to nimodipine in an animal model of subarachnoid hemorrhage." | 3.76 | Effects of ebselen versus nimodipine on cerebral vasospasm subsequent to experimental subarachnoid hemorrhage in rats. ( Acikgoz, B; Acikgoz, S; Ankarali, H; Bahadir, B; Bektas, S; Gul, S; Hanci, V; Kalayci, M; Ugurbas, E, 2010) |
| " The monkeys were randomly divided into three groups according to Ebselen dosage: 1) no dosage or non-treated group; 2) high-dose Ebselen group; and 3) low-dose Ebselen group." | 1.31 | Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates. ( Handa, Y; Kaneko, M; Kobayashi, H; Kubota, T; Takeuchi, H; Tsuchida, A, 2000) |
| "Twenty-five dogs were exposed to subarachnoid hemorrhage and divided into two groups." | 1.30 | Ebselen (DR3305) ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model. ( Asano, T; Hori, T; Masayasu, H; Nishiyama, M; Shimizu, T; Watanabe, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gul, S | 1 |
| Bahadir, B | 1 |
| Hanci, V | 1 |
| Acikgoz, S | 1 |
| Bektas, S | 1 |
| Ugurbas, E | 1 |
| Ankarali, H | 1 |
| Kalayci, M | 1 |
| Acikgoz, B | 1 |
| Watanabe, T | 1 |
| Nishiyama, M | 1 |
| Hori, T | 1 |
| Asano, T | 2 |
| Shimizu, T | 1 |
| Masayasu, H | 1 |
| Saito, I | 1 |
| Sano, K | 1 |
| Takakura, K | 1 |
| Abe, H | 1 |
| Yoshimoto, T | 1 |
| Kikuchi, H | 1 |
| Ohta, T | 1 |
| Ishibashi, S | 1 |
| Handa, Y | 1 |
| Kaneko, M | 1 |
| Takeuchi, H | 1 |
| Tsuchida, A | 1 |
| Kobayashi, H | 1 |
| Kubota, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ebselen and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Antioxidants; Azoles; Brain Ischemia; Double-Blind Method; Female; Humans; Incidence; Intracra | 1998 |
3 other studies available for ebselen and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Effects of ebselen versus nimodipine on cerebral vasospasm subsequent to experimental subarachnoid hemorrhage in rats.
Topics: Analysis of Variance; Animals; Antioxidants; Azoles; Brain; Drug Administration Schedule; Female; In | 2010 |
Ebselen (DR3305) ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model.
Topics: Animals; Arachidonate 5-Lipoxygenase; Azoles; Basilar Artery; Dogs; Hydroxyeicosatetraenoic Acids; I | 1997 |
Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates.
Topics: Animals; Antioxidants; Azoles; Cerebral Angiography; Chronic Disease; Dose-Response Relationship, Dr | 2000 |